- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2025 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Featured Content
European Biotech Targeting Anti-ageing
Oct 2nd 2024
Novel mitophagy inducers and gene therapies that restore cellular function and decelerate the ageing process.
Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?
Mar 4th 2024
Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.
Training for Operational Excellence
Dec 3rd 2023
The bio/pharmaceutical industry is struggling with the challenge of staffing and training.
Billions of Reasons to be Buoyant
Sep 2nd 2023
Pharma's ability to continually reinvent itself will be critical in growing future business operations.
Latest Videos
Latest News
GSK to Acquire Aiolos Bio, Expands Respiratory Portfolio
January 9th 2024
In a deal worth up to $1.4 billion, GSK aims to acquire Aiolos Bio and gain an expanded pipeline of biologic-based respiratory therapeutic candidates.
WuXi AppTec Expands Peptide and API Manufacturing
January 9th 2024
The expansion will boost solid-phase peptide synthesis total reactor volume to 32,000 L.
Boehringer Ingelheim and Ribo Partner on RNA-based Liver Disease Therapeutics
January 5th 2024
Under the collaboration, Boehringer Ingelheim and Ribo will develop RNA-based therapeutics to treat NASH/MASH.
Roche to Acquire Point-of-Care Technology from LumiraDx in $350 Million Deal
January 4th 2024
Roche will acquire select parts of the LumiraDx group related to that company’s point-of-care technology, which integrates multiple tests on a single instrument.
AstraZeneca Poised to Acquire Cell Therapy Developer, Gracell, in Deal Valued at $1.2 Billion
January 4th 2024
AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.
QurAlis Opens European Headquarters in The Netherlands
January 4th 2024
The new Europe headquarters will be the hub for the company’s European operations, including production of product.
Replay Signs Exclusive Licensing Agreements with NIH and Miltenyi Biotec for Cell Therapy Development and Manufacturing
December 29th 2023
Through Syena, its oncology-focused product company, Replay will develop and manufacture T-cell receptor and natural killer cell therapies with the NIH and Miltenyi Biotec.
Ultragenyx Picks Andelyn Biosciences to Manufacture Novel Gene Therapy for Sanfilippo Syndrome
December 27th 2023
Andelyn Biosciences has been selected by Ultragenyx to manufacture UX111, that company’s gene therapy for treating Sanfilippo Syndrome.
Daiichi Sankyo Partners with Depixus to Accelerate RNA-Targeted Drug Discovery
December 20th 2023
Under a collaboration, Daiichi Sankyo and Depixus will use Depixus’ MAGNA technology to accelerate drug discovery efforts of RNA-targeted therapeutics.
NightHawk Biosciences Shifts into a Pure-Play Large-Molecule CDMO
December 20th 2023
Following the divestiture of its Elusys subsidiary and other non-core assets, NightHawk Biosciences will transform into a pure-play large-molecule CDMO.